Anjali Shailani, Raman Preet ,Kaur Anjana Munshi.comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors. Med Oncol. 2018 Jan 31;35(3):18.
 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.
 RB1 and TP53 Loss Promotes Lineage Plasticity in Prostate Cancer. Cancer Discovery, 2017, 7(3):244.
 Chen M, Zhang J, Sampieri K, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics, 2018, 50(2).
 Phin S, Moore M W, Cotter P D. Genomic Rearrangements of PTEN in Prostate Cancer. Frontiers in Oncology, 2013, 3:240.
 ESMO 2019. PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations.